Title

Biomarkers of Parkinson's Disease: Screening Vital Signs and Routine Blood Tests

Authors' names and affiliations

Hirota Iwaki MD^{1,2}, Hampton L. Leonard MS^{1,2}, Sara Bandrés-Ciga PhD¹, Cornelis Blauwendraat PhD¹, Mary B. Makarios BSc¹, Sonja W. Scholz MD^{3,4}, Noriko Nishikawa MD⁵, Faraz Faghri PhD^{1,6}, Mark Frasier PhD⁷, J. Raphael Gibbs PhD¹, Andrew B. Singleton PhD¹, Mike A. Nalls PhD^{1,2}, Dena G. Hernandez PhD¹.

1. Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
2. Data Tecnica International, Glen Echo, MD, USA.
3. Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
4. Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA.
5. Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Japan
6. Department of Computer Science, University of Illinois at Urbana-Champaign, Champaign, IL, USA
7. The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.

Corresponding author

Dena G. Hernandez Ph.D.

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health

35 Convent Drive, Bethesda, MD, USA 20892

Phone Number: 301-435-7606

Fax Number: 301-451-7295

Abstract

BACKGROUND: There is a need for reliable, objective, and easily accessible biomarkers for Parkinson's disease.

OBJECTIVES: The purpose of this study was to screen biomarkers from vital signs and routine blood tests.

METHODS: Longitudinal data of up to 7 years of vital signs and routine blood tests from 418 patients with Parkinson's disease (PD) untreated at baseline and 185 individuals without any neurological disease were analyzed using linear mixed models. We nominated the biomarkers whose main associations with the measurements were significant as differentiating biomarkers. Similarly, we nominated the interaction effects between biomarkers and time from baseline as progression biomarkers. We tested for 49 biomarkers, and multiple comparison was corrected with the false-discovery-rate of 0.05. We further evaluated the potential biomarkers with regard to their importance in diagnosis prediction and their association with sub-scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). We also assessed the relationship of the associations using bioinformatics.

RESULTS: Heart rate, systolic blood pressure, white blood cell fractions, neutrophil counts, serum albumin, sodium and AST were different between PD and controls. The causality or genetic correlations of these biomarkers to PD were not observed. Chronological changes in height, albumin, hemoglobin, and bicarbonate were different in PD. These biomarkers were associated with MDS-UPDRS sub-scores.

Conclusions In this study, the potential of some easily accessible biomarkers for diagnosis and disease progression was presented. Further investigation of the mechanisms underlying these associations is important for a deeper understanding of the disease and the better management of patients.

Key words

biomarker;Parkinson's disease;neutrophil;albumin;progression

Introduction

There is an ongoing effort to identify reliable and objective biomarkers for Parkinson's disease (PD) that could assist with diagnosis or change with progression [1]. In addition, studying the mechanisms underlying the associations between biomarkers and a disease is important to understand the disease. One of the most intensively studied candidate biomarkers is the measurement of α -synuclein levels in the cerebrospinal fluid (CSF). The concentration of α -synuclein in the CSF has been consistently reported as being decreased in PD patients [2–4]. It may also be a prognostic marker for motor symptoms [5,6]. Because of the large variance, however, the sensitivity (78-88%) and specificity (40-57%) of α -synuclein levels in the CSF are not high enough to use in clinical practice [1]. Additionally, lumbar puncture is not within the range of daily medical procedures. Ideally, biomarkers should be easily accessible and inexpensive.

Here, we screened for biomarkers in vital signs and routine blood laboratory tests, including hematology and chemistry measurements. We were interested in 2 types of biomarkers: (1) biomarkers differentiating cases from controls regardless of time (differentiating biomarkers) and (2) biomarkers associated with the progression of the disease (progression biomarkers). To identify these 2 types of biomarkers, we studied longitudinal data of idiopathic PD patients and controls from the Parkinson's Progression Marker Initiative (PPMI). Specifically, for differentiating biomarkers, we examined measurements discriminating between PD cases and controls over time. For progression biomarkers, we screened the measurements for which having PD was associated with a different rate of change than not having PD, knowing that PD is a progressive disease. Next, we evaluated the characteristics of the relationships between the nominated blood biomarkers and PD, using genetic approaches. Namely, we conducted linkage disequilibrium (LD) score regressions to assess the genetic correlations between the biomarkers and PD. We also applied 2-sample Mendelian randomization to evaluate causality in the relationships of the associations. We assessed the quality of the nominated differentiating biomarkers and α -synuclein levels in the CSF. We

also examined the association between progression biomarkers and sub-scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [7].

Method

Study cohort:

The participants in this study included 418 patients with PD (cases) and 185 individuals without any neurological disease (controls) from the PPMI. Detailed information regarding the PPMI is available at www.ppmi-info.org. The cases of the study were untreated PD patients who had been diagnosed less than 2 years before enrollment. Most of them had blood samples taken at baseline and then annually. The vital signs were also recorded at each visit. The PPMI is an ongoing study, and we downloaded the data from the website on August 28, 2019 and used the observations from the first 7 years (up to visit 14). The PPMI study was registered at ClinicalTrials.gov (NCT01141023), approved by the institutional review board at each site, and the participants provided written informed consent.

Laboratory tests:

The routine clinical laboratory tests listed below were performed at baseline and annual follow-ups. A central laboratory (Covance Inc., Princeton, NJ, USA) was used to guarantee identical analysis methods and consistent normal ranges and, thus, common interpretation of laboratory changes. The hematology tests included red blood cell counts (TI/L), hemoglobin (g/L), hematocrit (no unit), white blood cell (WBC) counts (GI/L), neutrophil counts (GI/L) and their ratio in WBC (%), eosinophil counts (GI/L) and their ratio in WBC (%), basophil counts (GI/L) and their ratio in WBC (%), monocyte counts (GI/L) and their ratio in WBC (%), lymphocyte counts (GI/L) and their ratio in WBC (%), and platelet counts (GI/L). The chemistry tests included total protein (g/L), albumin (g/L), total bilirubin ($\mu\text{mol/L}$), alkaline

phosphatase (U/L), aspartate aminotransferase (U/L), alanine aminotransferase (U/L), serum sodium (mmol/L), serum potassium (mmol/L), serum bicarbonate (mmol/L), serum chloride (mmol/L), calcium (mmol/L), creatinine (μ mol/L), urea nitrogen (mmol/L), serum uric acid (μ mol/L), and serum glucose (mmol/L).

The concentration of alpha-synuclein in the CSF samples collected for the PPMI were analyzed using an ELISA assay available commercially from BioLegend (cat # 844101).

Vital signs and MDS-UPDRS:

Heart rate (supine and standing), blood pressure (supine and standing), and oral temperature were measured at every visit. The supine blood pressure and heart rate were determined after 1-3 minutes of quiet rest, and the standing blood pressure and heart rate were determined after 1-3 minutes in the standing position. Weight and height were collected at baseline and annually or bi-annually according to the visit schedule. In addition to the measured vital signs, we created some new outcomes. We examined the differences between the measurements taken in the supine position and those taken in the standing position for systolic blood pressure, diastolic blood pressure, and heart rate. We also examined the ratio of these measurements: We divided the value in the standing position by the value in the supine position. In addition, sub-scores on the MDS-UPDRS part I, part II, and part III at baseline were used in the exploratory analysis of progression markers.

Statistical analysis:

Primary analysis: Nominating biomarkers among vital signs and lab measurements

We used linear mixed effect models including terms indexing having or not having PD (PD status), years from baseline, interaction between PD status and years from baseline, sex, age at baseline, BMI, the dosages of PD drugs (levodopa, MAO-B inhibitor, pramipexole, ropinirole, and amantadine), and random terms of intercept and slope for each individual. In this model, the beta coefficient for the PD status term

(main term) corresponded to the difference between PD cases and controls over time, while the beta coefficient for the interaction between PD status and years from baseline term(interaction term) corresponded to the difference between PD cases and [8] controls in terms of the rate of change between PD and controls over time. To correct multiple comparison, we calculated qvalues [8] and applied 2-tailed tests at the false discovery rate (FDR) of 0.05 for the number of tested models (49) and nominated differentiating biomarkers whose main term was significant and progression biomarkers whose interaction term was significant. To avoid the impact of outliers on the analyses, we excluded the data points that had outcomes outside of mean $\pm$ 4 SD from the analyses. For the nominated differentiating/progression biomarkers, we also checked the mean difference between PD cases and controls after adjusting for age, sex and BMI; we checked the mean difference between PD cases and controls at 0 (baseline) and at the first-, second-, third-, fourth-, and fifth-year. The model specifications of these analyses are provided in the supplemental materials, and the analyses were conducted in R version 3.6.3.

Causal inferences and genetic correlations

We applied LD score regression (LDSC) and 2-sample Mendelian randomization to explore genetic correlations and causal inferences between PD and the nominated biomarkers, respectively. LDSC is based on the premise that single nucleotide polymorphisms (SNPs) in regions of high LD tag a greater proportion of the genome and will therefore show stronger associations, on average, than SNPs in regions of low LD [9]. Using the known LD structure of a reference SNP panel, reliable estimates of shared genetic risk can be estimated. We implemented LDSC v1.0.1, using default settings to calculate overlapping genetic etiologies from the most recent PD genome-wide association study (GWAS) summary statistics [10] and publicly available summary statistics for some of the nominated biomarkers, including neutrophil percentage of white blood cells, neutrophil count, lymphocyte counts, lymphocyte

percentage of white blood cells, monocyte percentage of white blood cells, and hemoglobin concentration [11]. Summary statistics for the remaining biomarkers were not available at the time of the analysis. To explore the causal effects of the nominated biomarkers on PD risk, we then implemented 2-sample Mendelian randomization (MR) using MR Base under default settings [12]. We undertook harmonization was to rule out strand mismatches and to ensure alignment of SNP effect sizes. Within each individual nominated biomarker (exposure GWAS), We calculated Wald ratios for each extracted SNP by dividing the per-allele log-odds ratio (or beta) of that variant in the PD GWAS data by the log-odds ratio (or beta) of the same variant in the exposure data. For MR analysis, we applied inverse-variance weighted (IVW) and Egger methods to examine the relationship between the individual nominated biomarkers and PD. We studied the effects of pleiotropy and heterogeneity for each inference by undertaking sensitivity analyses. We performed reverse causality analyses to determine whether PD was causally linked to any of the nominated biomarkers. We only reported a relationship only when it was significant (raw p-value < 0.05) in both evaluations with IVW and Egger in the same direction and not having a reverse causation.

Discrimination ability of blood biomarkers

To evaluate the diagnostic accuracy of the nominated blood biomarkers, we trained and tested different machine learning algorithms to classify patients as PD cases or healthy controls at baseline. First, we employed lasso regression to eliminate superfluous variables that were not contributing to model accuracy. We then tested 4 different models on different combinations of biomarker and vital sign variables alongside the covariates that were kept constant across all models: age, sex, and BMI. We built the first model using α -synuclein, age, sex, and BMI. We built the second model using the blood biomarkers nominated by lasso (neutrophil %, monocyte, albumin, aspartate aminotransferase (AST), serum sodium) and the constant covariates. The third model used the same variables as the second, but three vital signs (systolic blood pressure in the standing position, heart rate in the standing position, and heart rate in the supine position) were added. The fourth model combined all the nominated variables and covariates used in the previous models. For each model, we tested 12 different binary classification algorithms using 5-

fold cross validation (see supplemental materials for details). The best-performing algorithm was chosen according to the largest area under the curve (AUC), a measure of model performance.

The association between progression markers and MDS-UPDRS sub-scores

The associations between the MDS-UPDRS sub-scores (parts I, II and III) and the nominated progression markers were tested. We hypothesized that if the nominated progression markers were truly associated with progression, they may be associated with the MDS-UPDRS sub-scores at baseline among PD patients. Linear regression models were applied, adjusting for sex, age and BMI at the significance level of 0.05, two-tailed.

Results

Table 1 shows the characteristics of the participants, the number of observations each year, the vital signs and the blood test results at baseline. In total, we had 603 participants and 3,592 data points in the current study. In the primary analysis, we nominated 10 differentiating biomarkers and 7 progression biomarkers among 19 vital sign associated outcomes and 30 different lab tests. Albumin and serum sodium were both differentiating and progression biomarkers. Table 2 presents the results for the 15 nominated biomarkers. (All the results can be found in Supplemental Table 1). Some of these biomarkers were correlated. When we analyzed the correlation coefficients of these measurements using the baseline data of controls, %WBC of lymphocyte and %WBC of neutrophil were highly correlated (correlation coefficient, $\rho = -0.95$), indicating these two outcomes were effectively one (Supplemental [Figure 1](#)). There were also moderate correlations between supine and standing heart rates, cell counts and their %WBC for neutrophils and lymphocytes, and concentrations of serum sodium and chloride.

We observed a higher heart rate in the supine/standing position and lower systolic blood pressure in patients with PD. In the current study period, the differences between the supine and standing position in terms of blood pressure and heart rate were not significantly different, nor had they significantly increased over time, in patients with PD. These vital signs may suggest a slightly hypovolemic state among people with PD. A higher albumin concentration in the blood observed in PD cases aligned with this hypothesis, but we did not have adequate measurements to further confirm it. A negative change in height over time was another biomarker in the vital signs. Longitudinal changes in height in people with PD have rarely been reported, but given that slouching and scoliosis are common symptoms, they may explain the progressive lowering of height seen in the cases.

In the blood, the composition of white blood cells in PD cases was different to the composition of white blood cells in controls. The fraction of neutrophils had the strongest association with PD, and the association between PD and the fraction of lymphocytes may have been through the negative correlations between the fraction of lymphocytes and that of neutrophils. Among the chemistry tests, we nominated the concentration of AST as a differentiating biomarker, but we did not nominate alanine aminotransferase (ALT) as a differentiating biomarker. The discrepancy between the 2 enzymes may indicate the existence of reduced muscle volume in PD patients, even in the early phase. Further, we observed that the albumin and hemoglobin levels of PD patients were dropping faster than those of controls. This may suggest a nutrition deficit developing over time, but the average weight and its changing rate were not significantly different in PD patients during the study period. Finally, the composition of electrolytes changed over time among PD cases relative to controls. We adjusted for typical anti-PD medications, but we did not adjust for other drugs including laxative drugs, which might have influenced the results.

For the nominated biomarkers, we examined the mean difference between PD cases and controls at each visit after adjusting for sex, age and BMI (Figure 1); we also examined unadjusted boxplots of PD cases

and controls at each visit (Supplemental Figure 2). These plots were useful to assess the chronological trends of the differences. All the nominated differentiating biomarkers were significantly different at baseline, suggesting the utility of these biomarkers for detecting PD in its early phase. Notably, the differences between PD cases and controls in terms of the differentiating biomarkers were relatively stable over time, indicating the robustness of these biomarkers against PD treatment and disease-associated changes. By contrast, the differences between PD cases and controls in terms of the nominated progression markers were changing over time, as we expected. We observed a sudden drop in the mean difference in albumin levels at the year-4 visit. We could not identify the particular reason for this phenomenon, but when we conducted the same analysis without using the year-4 visits, the model still suggested that the albumin level was both a differentiating biomarker and a progression biomarker.

The genetic approaches using LD score regression and Mendelian randomization did not indicate any association mechanism of shared genetic etiology between the nominated blood biomarkers and PD (Supplemental Table 3). Additionally, none of the assessed biomarkers showed any significant causal genetic relationship with PD risk or the presence of reverse causality (Supplemental Table 4). Sensitivity analyses did not find any sign of heterogeneity or horizontal pleiotropy.

When comparing the top performing predictive models, the accuracy of the model using basic variables (age, sex, BMI) plus α -synuclein (model 1) was similar to the model using the basic variables and blood variables (model 2) (Figure 2). The mean AUC increased when we added vital signs to model 2 (model 3) and further increased when we added α -synuclein (model 4). We performed feature ranking to determine the variables that contributed the most to each model. age, BMI, neutrophil (%), AST, albumin and serum sodium were nominated in multiple models.

Of the 7 progression biomarkers, 4 were associated with MDS-UPDRS sub-scores at baseline in PD. Sub-scores on MDS-UPDRS part I were significantly worse in patients with lower blood albumin levels,

lower hemoglobin levels, or taller height. Sub-scores on MDS-UPDRS part III were worse in people with lower levels of serum bicarbonate (Supplemental Table 2). The other nominated progression biomarkers, however, were not associated with MDS-UPDRS sub-scores.

Discussion

Among the biomarkers we screened, the neutrophil fraction in WBC had the strongest signal as a differentiating biomarker. In methylation data analyses, the estimated fraction of granulocytes has repeatedly been reported to be highly associated with PD status [13,14]. The current results suggest that this association may be driven by the fraction of neutrophils, which constitute the dominant portion of granulocytes. The neutrophil-lymphocyte ratio (NLR) has also been studied previously but its association with PD was inconclusive [15,16]. The NLR and neutrophil fraction in WBC were correlated in the current data, but the strength of the associations with PD was stronger for the neutrophil fraction (unadjusted $P = 5.75E-07$) than for the NLR (unadjusted $P = 4.42E-06$). Recently, a nested case-control study screening peripheral immune biomarkers in a large population cohort in Sweden reported that a lower concentration of white blood cells, especially lymphocytes was associated with an increased incidence of PD [17]. In the current study, the direction of the association between lymphocyte counts and PD was concordant with this finding but did not reach the FDR threshold ($P = 0.053$). Moreover, the lymphocyte count in the current data was moderately associated with the strongest predictor, neutrophil fraction of WBC ($\rho = -0.57$). Further investigations are needed to identify the most important measurement representing the differences between PD cases and controls in terms of hematologic profiles. The reason for the change in white blood cell composition is not well known, although inflammation is hypothesized to be a major pathogenic factor for PD [18]. Inflammatory cytokines may play a role. A nested case-control study of a prospective cohort reported that higher concentrations of Interleukin-6 were found in the blood collected on average 4.3 years before the diagnosis [19,20]. It is also interesting that a change in the gut bacterial population has been reported in patients with PD as well as those with REM

sleep behavior disorders [20], although studies of the association between the hematology profile and the gut bacterial population are rare. We conducted an ad-hoc test to assess the association between the prevalence of constipation and the neutrophil fraction in WBC in PD patients at baseline, but the association was null ($P = 0.92$).

Based on the analyses applying genetic approaches which did not suggest any shared genetic etiology or causality of the association mechanisms, we do not have any evidence that the associations in the current study were more than the disease associated changes. Still, studying the reasons behind these associations is warranted because it may lead to the identification of important disease mechanisms or the better management of patients.

The prediction models using basic variables and biomarkers had relatively low AUCs and they were not useful for differentiating PD patients from healthy controls in daily practice. Nevertheless, the ranking of variables contributing to the prediction models may be useful to prioritize the biomarkers for further research.

The current study has 3 strengths. First, we leveraged the longitudinal data not only to obtain higher power in detecting differentiating biomarkers but also as an opportunity to find progression biomarkers. Second, the vital signs and laboratory tests we screened were commonly obtained in a routine clinical setting. Although this study was exploratory, we demonstrated the potential value of these measurements to assess the differences between PD cases and controls and to assess the disease progression. Although these biomarkers were substantially overlapped between cases and controls and may not be useful for diagnosis, the study provided some hypotheses explaining the differences which can be confirmed in everyday practice. Third, unlike many other biomarker studies, in which PD patients at various stages were included and compared with controls, this study included PD patients who were all at an early disease stage and untreated at baseline. In this setting, we were able to untangle the impact of treatment

and PD-associated changes in the progression stage. It is important to note that all the differentiating biomarkers were confirmed to be significantly different in PD cases than in controls at baseline.

The major limitation is that we did not approach the individual mechanisms underlying the differences between PD cases and controls in terms of these biomarkers. As similar studies of this size and span are rare, the results from this effort will be useful to generate hypotheses that ought to be tested further. Another limitation relates to the setting of the study: Most of the cases in the study were in relatively early stages of the disease. Longer observations will be necessary to identify progression markers relevant to the later stage of the disease.

In conclusion, we screened vital signs and common blood test measurements over more than 5 years to identify differentiating/progression biomarkers of PD. A total of 16 measurements were nominated. These associations should be studied further.

Acknowledgment

This study was supported by the Intramural Research Program the National Institute on Aging (Z01 AG000949-02), and the Michael J. Fox Foundation for Parkinson's Research. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Neurological Disorders and Stroke (project number: 1ZIANS003154).

Data used in preparation of this article were obtained from the MJFF-sponsored PPMI database (www.ppmi-info.org/data). For up-to-date information on these studies, visit www.ppmi-info.org.

PPMI – a public-private partnership – is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali Incorporated, GE Healthcare, Genentech, GlaxoSmithKline, Eli Lilly and Company, Lundbeck, Merck & Co., Meso Scale Discovery, Pfizer,

Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier Laboratories, Takeda, Teva, UCB, Verily, Voyager Therapeutics, and Golub Capital (www.ppmi-info.org/fundingpartners).

Conflict of Interest

The authors have no conflict of interest to report.

References

- [1] Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol.* **18**, 573–586.
- [2] Sako W, Murakami N, Izumi Y, Kaji R (2014) Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis. *Mov. Disord.* **29**, 1599–1605.
- [3] Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, Calabresi P, Parnetti L (2017) Diagnostic utility of cerebrospinal fluid α -synuclein in Parkinson's disease: A systematic review and meta-analysis. *Mov. Disord.* **32**, 1389–1400.
- [4] Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kiebertz K, Chahine LM, Marek K, Galasko D (2019) Longitudinal analyses of cerebrospinal fluid α -Synuclein in prodromal and early Parkinson's disease. *Mov. Disord.* **34**, 1354–1364.
- [5] Hall S, Surova Y, Ohrfelt A, Zetterberg H, Lindqvist D, Hansson O (2015) CSF biomarkers and clinical progression of Parkinson disease. *Neurology* **84**, 57–63.
- [6] Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M (2018) REM behavior disorder

- predicts motor progression and cognitive decline in Parkinson disease. *Neurology* **91**, e894–e905.
- [7] Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. *Mov. Disord.* **22**, 41–47.
- [8] Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. *Proc. Natl. Acad. Sci.* **100**, 9440–9445.
- [9] Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale BM (2015) LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295.
- [10] Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol J-C, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, Adames-Gómez AD, Aguilar M, Aitkulova A, Akhmetzhanov V, Alcalay RN, Alvarez I, Alvarez V, Bandres-Ciga S, Barrero FJ, Bergareche Yarza JA, Bernal-Bernal I, Billingsley K, Blauwendraat C, Blazquez M, Bonilla-Toribio M, Botía JA, Boungiorno MT, Bras J, Brice A, Brockmann K, Bubb V, Buiza-Rueda D, Cámara A, Carrillo F, Carrión-Claro M, Cerdan D, Chelban V, Clarimón J, Clarke C, Compta Y, Cookson MR, Corvol J-C, Craig DW, Danjou F, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Escott-Price V, Ezquerro M, Faghri F, Feliz C, Fernández M, Fernández-Santiago R, Finkbeiner S, Foltynie T, Gan-Or Z, Garcia C, García-Ruiz P, Gasser T, Gibbs JR, Gomez Heredia MJ, Gómez-Garre P, González MM, Gonzalez-Aramburu I, Guelfi S, Guerreiro R, Hardy J, Hassin-Baer S, Hernandez DG, Heutink P,

Hoenicka J, Holmans P, Houlden H, Infante J, Iwaki H, Jesús S, Jimenez-Escrig A, Kaishybayeva G, Kaiyrzhanov R, Karimova A, Kia DA, Kinghorn KJ, Koks S, Krohn L, Kulisevsky J, Labrador-Espinosa MA, Leonard HL, Lesage S, Lewis P, Lopez-Sendon JL, Lovering R, Lubbe S, Lungu C, Macias D, Majamaa K, Manzoni C, Marín J, Marinus J, Marti MJ, Martinez M, Martínez Torres I, Martínez-Castrillo JC, Mata M, Mencacci NE, Méndez-del-Barrio C, Middlehurst B, Mínguez A, Mir P, Mok KY, Morris HR, Muñoz E, Nalls MA, Narendra D, Noyce AJ, Ojo OO, Okubadejo NU, Pagola AG, Pastor P, Perez Errazquin F, Perinán-Tocino T, Pihlstrom L, Plun-Favreau H, Quinn J, R'Bibo L, Reed X, Rezola EM, Rizig M, Rizzu P, Robak L, Rodriguez AS, Rouleau GA, Ruiz-Martínez J, Ruz C, Ryten M, Sadykova D, Scholz SW, Schreglmann S, Schulte C, Sharma M, Shashkin C, Shulman JM, Sierra M, Siitonen A, Simón-Sánchez J, Singleton AB, Suarez-Sanmartin E, Taba P, Tabernero C, Tan MX, Tartari JP, Tejera-Parrado C, Toft M, Tolosa E, Trabzuni D, Valldeoriola F, van Hilten JJ, Van Keuren-Jensen K, Vargas-González L, Vela L, Vives F, Williams N, Wood NW, Zharkinbekova N, Zharmukhanov Z, Zholdybayeva E, Zimprich A, Ylikotila P, Shulman LM, von Coelln R, Reich S, Savitt J, Agee M, Alipanahi B, Auton A, Bell RK, Bryc K, Elson SL, Fontanillas P, Furlotte NA, Huber KE, Hicks B, Jewett EM, Jiang Y, Kleinman A, Lin K-H, Litterman NK, McCreight JC, McIntyre MH, McManus KF, Mountain JL, Noblin ES, Northover CAM, Pitts SJ, Poznik GD, Sathirapongsasuti JF, Shelton JF, Shringarpure S, Tian C, Tung J, Vacic V, Wang X, Wilson CH, Anderson T, Bentley S, Dalrymple-Alford J, Fowdar J, Gratten J, Halliday G, Henders AK, Hickie I, Kassam I, Kennedy M, Kwok J, Lewis S, Mellick G, Montgomery G, Pearson J, Pitcher T, Sidorenko J, Silburn PA, Vallerga CL, Visscher PM, Wallace L, Wray NR, Xue A, Yang J, Zhang F (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102.

- [11] Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F, Kostadima MA, Lambourne JJ, Sivapalaratnam S, Downes K, Kundu K, Bomba L, Berentsen K, Bradley JR, Daugherty LC, Delaneau O, Freson K, Garner SF, Grassi L, Guerrero J, Haimel M,

- Janssen-Megens EM, Kaan A, Kamat M, Kim B, Mandoli A, Marchini J, Martens JHA, Meacham S, Megy K, O'Connell J, Petersen R, Sharifi N, Sheard SM, Staley JR, Tuna S, van der Ent M, Walter K, Wang S-Y, Wheeler E, Wilder SP, Iotchkova V, Moore C, Sambrook J, Stunnenberg HG, Di Angelantonio E, Kaptoge S, Kuijpers TW, Carrillo-de-Santa-Pau E, Juan D, Rico D, Valencia A, Chen L, Ge B, Vasquez L, Kwan T, Garrido-Martín D, Watt S, Yang Y, Guigo R, Beck S, Paul DS, Pastinen T, Bujold D, Bourque G, Frontini M, Danesh J, Roberts DJ, Ouwehand WH, Butterworth AS, Soranzo N (2016) The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell* **167**, 1415-1429.e19.
- [12] Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, Hemani G, Tansey K, Laurin C, Pourcain BS, Warrington NM, Finucane HK, Price AL, Bulik-Sullivan BK, Anttila V, Paternoster L, Gaunt TR, Evans DM, Neale BM (2017) LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279.
- [13] Horvath S, Ritz BR (2015) Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients. *Aging (Albany, NY)*. **7**, 1130–1142.
- [14] Henderson-Smith A, Fisch KM, Hua J, Liu G, Ricciardelli E, Jepsen K, Huentelman M, Stalberg G, Edland SD, Scherzer CR, Dunckley T, Desplats P (2019) DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. *Epigenetics* **14**, 365–382.
- [15] Akıl E, Bulut A, Kaplan İ, Özdemir HH, Arslan D, Aluçlu MU (2015) The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson's disease. *Neurol. Sci.* **36**, 423–428.
- [16] Ataç Uçar C, Gökçe Çokal B, Ünal Artık HA, İnan LE, Yoldaş TK (2017) Comparison of neutrophil–lymphocyte ratio (NLR) in Parkinson's disease subtypes. *Neurol. Sci.* **38**, 287–293.
- [17] Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, Fang F (2019) Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of

follow-up. *Ann. Neurol.* **86**, 913–926.

- [18] Kannarkat GT, Boss JM, Tansey MG (2013) The Role of Innate and Adaptive Immunity in Parkinson's Disease. *J. Parkinsons. Dis.* **3**, 493–514.
- [19] Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2007) Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease. *Am. J. Epidemiol.* **167**, 90–95.
- [20] Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P (2018) The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. *Mov. Disord.* **33**, 88–98.

Figure legend

Figure 1: The mean differences between cases and controls at each visit

Legend: The Y-axis shows the mean differences between controls and cases. Bars indicate the 95% confidence interval. Age, sex, and BMI were adjusted. The blue horizontal line is 0.

Prog = nominated as a progression biomarker; Diff = nominated as a differentiating biomarker.

Figure 2: AUC of the prediction models

Legend:

A. Model 1: Logistic regression. Variables: age(1), sex, BMI, and α -synuclein(2)

B. Model 2: Adaptive Boosting classifier. Variables: age(1), sex, BMI(2), neutrophil %(3), monocyte %, albumin(5), AST, and serum sodium(4)

C. Model 3: Linear Discriminant Analysis model. Variables: age, sex, BMI, neutrophil %(1), monocyte %(4), albumin(3), AST(5), serum sodium(2), systolic blood pressure in the standing position, heart rate in the standing position, and heart rate in the supine position(6)

D. Model 4: Linear Discrimination Analysis model. Variables: age(1), sex, BMI(2), neutrophil %(3), monocyte %, albumin, AST(4), serum sodium(7), systolic blood pressure in the standing position(6), heart rate in the standing position, heart rate in the supine position, and α -synuclein(5)

The numbers next to the variables indicate the rank of contribution to the model

Table 1. Baseline characteristics and selected vital signs and blood test results

	Control	PD
Total, N	185	418
Female, N (%)	69 (37.3)	145 (34.7)
Age at baseline, years (SD)	60.37 (11.03)	61.72 (9.77)
Age at diagnosis, years (SD)	-	61.17 (9.75)
BMI, kg/m ² (SD)	26.98 (4.54)	27.13 (4.65)
<u>Visits, N</u>		
Year 0	185	418
Year 1	170	379
Year 2	161	363
Year 3	153	355
Year 4	149	336
Year 5	144	309
Year 6	16	249
Year 7	85	120
<u>Vital signs</u>		
Oral Temperature, Celsius (SD)	36.51 (0.44)	36.53 (0.40)
Heart Rate (supine), bpm (SD)	65.02 (9.24)	67.90 (10.99)**
Heart Rate (standing), bpm (SD)	71.94 (10.39)	75.36 (12.09)**
SBP (supine), mmHg (SD)	132.48 (17.00)	130.96 (17.31)
DBP (supine), mmHg (SD)	77.60 (10.86)	77.69 (10.96)
SBP (standing), mmHg (SD)	129.73 (17.87)	126.19 (17.01)*
DBP (standing), mmHg (SD)	81.07 (11.31)	79.37 (11.03)
<u>Baseline blood tests</u>		
RBC, T/L (SD)	4.70 (0.41)	4.66 (0.43)
WBC, G/L (SD)	6.14 (1.78)	6.18 (1.51)
Neutrophils, % WBC (SD)	59.58 (8.27)	63.04 (7.93)***
Lymphocytes, % WBC (SD)	30.12 (7.84)	27.26 (7.25)***
Monocytes, % WBC (SD)	6.65 (1.72)	6.29 (1.62)*
Eosinophils, % WBC (SD)	2.80 (1.82)	2.61 (2.24)
Hematocrit, (SD)	0.42 (0.04)	0.41 (0.04)
Hemoglobin, g/L (SD)	142.85 (12.48)	142.50 (12.56)
Albumin, g/L (SD)	40.50 (2.64)	40.99 (2.81)*
Serum Sodium, mmol/L (SD)	140.20 (2.07)	140.70 (2.26)*
Serum Bicarbonate, mmol/L (SD)	24.19 (2.37)	24.22 (2.40)
Serum Chloride, mmol (SD)	102.89 (2.45)	103.07 (2.30)
Serum Potassium, mmol/L (SD)	4.29 (0.38)	4.25 (0.33)
AST (SGOT), U/L (SD)	24.38 (6.72)	23.45 (12.87)

*, p<0.05; **, p<0.01; ***, p<0.001; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Beta coefficients for PD (Main effect) and PD*Year (Interaction effect) in linear mixed models

Test Groups	Test Name	Unit	N_ppl	N_obs	Main Effect			Interaction effect			Differentiating Biomarker	Progression Biomarker
					Beta	SE	P _{FDR}	Beta	SE	P _{FDR}		
Vital Sign	Height	cm	603	3531	1.385	0.590	0.0595	-0.169	0.060	0.0481		Yes
Vital Sign	HR (supine)	bpm	602	3522	2.780	0.774	0.0038	0.210	0.169	0.4109	Yes	
Vital Sign	HR (standing)	bpm	600	3519	3.221	0.839	0.0022	0.061	0.189	0.8326	Yes	
Vital Sign	SBP (standing)	mmHg	601	3519	-3.577	1.218	0.0185	0.264	0.290	0.5234	Yes	
Hematology	Hemoglobin	g/L	600	3297	-0.393	0.892	0.7178	-0.489	0.167	0.0432		Yes
Hematology	Neutrophils (%)	% WBC	600	3291	3.222	0.639	2.8E-05	-0.195	0.115	0.2205	Yes	
Hematology	Lymphocytes (%)	% WBC	598	3286	-2.403	0.576	8.3E-04	0.146	0.101	0.3196	Yes	
Hematology	Monocytes (%)	% WBC	600	3292	-0.382	0.128	0.0178	0.031	0.028	0.4458	Yes	
Hematology	Neutrophils	GI/L	599	3286	0.283	0.092	0.0155	-0.025	0.017	0.3239	Yes	
Chemistry	Albumin	g/L	602	3327	0.688	0.202	0.0057	-0.173	0.046	0.0027	Yes	Yes
Chemistry	Serum Sodium	mmol/L	602	3331	0.465	0.177	0.0431	0.165	0.042	0.0020	Yes	Yes
Chemistry	Serum Potassium	mmol/L	602	3337	-0.022	0.024	0.4660	0.017	0.006	0.0481		Yes
Chemistry	Serum Bicarbonate	mmol/L	602	3324	0.191	0.165	0.3452	0.165	0.039	0.0010		Yes
Chemistry	Serum Chloride	mmol/L	602	3335	0.014	0.190	0.9470	0.107	0.040	0.0493		Yes
Chemistry	AST (SGOT)	U/L	602	3285	-1.737	0.487	0.0038	-0.202	0.104	0.1771	Yes	

N_ppl, Number of participants in the analysis; N_obj, Number of observations in the analysis; Beta, beta coefficient; SE, standard error of the beta coefficient; PFDR, FDR adjusted P; HR, heart rate; SBP, systolic blood pressure.

Figure 1

Figure 2

Supplemental material

Supplemental Figure 1: Correlation coefficients of the nominated biomarkers in the controls at baseline

Legend: Some of the nominated biomarkers were highly correlated.

Supplemental Figure 2: Boxplots of the unadjusted values of the biomarkers at each visit, sex stratified.

Supplemental Table 1: All results of the primary analysis

Supplemental Table 2: Associations between the progression biomarkers and the MDS-UPDRS sub-scores of patients with PD at baseline

Supplemental Table 3: Genetic correlations between Parkinson's disease and the nominated biomarkers

Supplemental Table 4: Two-sample Mendelian randomization between Parkinson's disease and the nominated biomarkers

Appendix. Model specifications

Supplemental Figure 1:

Correlation coefficients of the nominated biomarkers in the controls at baseline

Some of the nominated biomarkers were highly correlated.

Supplemental Figure 2:

Boxplots of the unadjusted values of the biomarkers at each visit, sex stratified.

Supplemental Table 1. All results of the primary analysis

Test Groups	Test Name	Unit	N_ppl	N_obs	Main Effect				Interaction Effect			
					Beta	SE	P _{raw}	P _{FDR}	Beta	SE	P _{raw}	P _{FDR}
VITAL	Weight	kg	603	3527	1.34	1.25	0.284	0.376	-0.30	0.13	0.020	0.107
VITAL	Height	cm	603	3531	1.39	0.59	0.019	0.060	-0.17	0.06	0.005	0.048
VITAL	Temperature	Celsius	601	3509	0.02	0.03	0.599	0.667	0.00	0.01	0.579	0.692
VITAL	HR (supine)	bpm	602	3522	2.78	0.77	3.5E-04	0.004	0.21	0.17	0.215	0.411
VITAL	SBP (supine)	mmHg	602	3522	-1.60	1.19	0.180	0.276	0.54	0.29	0.060	0.177
VITAL	DBP (supine)	mmHg	602	3523	0.07	0.77	0.923	0.947	0.14	0.16	0.376	0.526
VITAL	HR (standing)	bpm	600	3519	3.22	0.84	1.3E-04	0.002	0.06	0.19	0.745	0.833
VITAL	SBP (standing)	mmHg	601	3519	-3.58	1.22	0.003	0.019	0.26	0.29	0.363	0.523
VITAL	DBP (standing)	mmHg	601	3522	-1.22	0.79	0.122	0.199	0.05	0.18	0.784	0.833
VITAL	MBP (supine)	mmHg	602	3522	-0.56	0.83	0.496	0.565	0.29	0.18	0.111	0.258
VITAL	MBP (standing)	mmHg	601	3522	-2.05	0.85	0.016	0.060	0.12	0.19	0.525	0.644
VITAL	SBP (difference)	mmHg	600	3507	-1.90	0.86	0.027	0.077	-0.25	0.22	0.240	0.436
VITAL	DBP (difference)	mmHg	600	3511	-1.05	0.54	0.054	0.114	-0.10	0.13	0.442	0.586
VITAL	HR (difference)	mmHg	599	3510	0.63	0.49	0.201	0.297	-0.24	0.12	0.045	0.177
VITAL	SBP (ratio)		600	3514	-0.01	0.01	0.044	0.097	0.00	0.00	0.282	0.446
VITAL	DBP (ratio)		601	3508	-0.01	0.01	0.074	0.135	0.00	0.00	0.360	0.523
VITAL	HR (ratio)		600	3503	0.01	0.01	0.490	0.565	0.00	0.00	0.065	0.177
VITAL	MBP (difference)	mmHg	600	3512	-1.39	0.58	0.016	0.060	-0.14	0.14	0.310	0.475
VITAL	MBP (ratio)		600	3513	-0.01	0.01	0.041	0.097	0.00	0.00	0.274	0.446
HEMAT	Monocytes	GI/L	599	3285	-0.02	0.01	0.066	0.130	0.00	0.00	0.725	0.833
HEMAT	Eosinophils	GI/L	599	3270	-0.01	0.01	0.092	0.155	0.00	0.00	0.779	0.833
HEMAT	Basophils	GI/L	600	3276	0.00	0.00	0.892	0.947	0.00	0.00	0.883	0.901
HEMAT	Platelets	GI/L	600	3267	-7.75	4.57	0.090	0.155	1.27	0.66	0.054	0.177
HEMAT	Neutrophils (%)	%	600	3291	3.22	0.64	5.8E-07	2.8E-05	-0.20	0.11	0.089	0.220
HEMAT	Lymphocytes (%)	%	598	3286	-2.40	0.58	3.4E-05	0.001	0.15	0.10	0.150	0.320
HEMAT	Monocytes (%)	%	600	3292	-0.38	0.13	0.003	0.018	0.03	0.03	0.273	0.446
HEMAT	Eosinophils (%)	%	600	3278	-0.27	0.11	0.019	0.060	0.01	0.02	0.778	0.833
HEMAT	Basophils (%)	%	599	3276	-0.04	0.03	0.147	0.232	0.01	0.01	0.090	0.220
HEMAT	Hematocrit		600	3294	0.00	0.00	0.267	0.363	0.00	0.00	0.065	0.177

HEMAT	RBC	TI/L	600	3299	-0.03	0.03	0.338	0.436	-0.01	0.01	0.056	0.177
HEMAT	Hemoglobin	g/L	600	3297	-0.39	0.89	0.659	0.718	-0.49	0.17	0.004	0.043
HEMAT	WBC	GI/L	598	3284	0.10	0.12	0.412	0.505	-0.02	0.02	0.278	0.446
HEMAT	Neutrophils	GI/L	599	3286	0.28	0.09	0.002	0.015	-0.02	0.02	0.159	0.324
HEMAT	Lymphocytes	GI/L	598	3287	-0.11	0.04	0.012	0.053	0.00	0.01	0.515	0.644
CHEMI	Total Bilirubin	umol/L	602	3275	0.81	0.39	0.037	0.096	-0.05	0.06	0.396	0.538
CHEMI	Serum Glucose	mmol/L	601	3298	0.12	0.06	0.041	0.097	-0.03	0.01	0.031	0.140
CHEMI	Total Protein	g/L	602	3340	0.71	0.30	0.019	0.060	-0.10	0.07	0.119	0.264
CHEMI	Albumin-QT	g/L	602	3327	0.69	0.20	0.001	0.006	-0.17	0.05	0.000	0.003
CHEMI	Alkaline Phosphatase-QT	U/L	602	3327	-0.10	1.44	0.947	0.947	0.53	0.24	0.029	0.140
CHEMI	Serum Sodium	mmol/L	602	3331	0.47	0.18	0.009	0.043	0.17	0.04	0.000	0.002
CHEMI	Serum Potassium	mmol/L	602	3337	-0.02	0.02	0.371	0.466	0.02	0.01	0.006	0.048
CHEMI	Serum Bicarbonate	mmol/L	602	3324	0.19	0.16	0.247	0.345	0.17	0.04	0.000	0.001
CHEMI	Serum Chloride	mmol/L	602	3335	0.01	0.19	0.942	0.947	0.11	0.04	0.007	0.049
CHEMI	Calcium (EDTA)	mmol/L	602	3332	0.02	0.01	0.028	0.077	0.00	0.00	0.984	0.984
CHEMI	Creatinine (Rate Blanked)	umol/L	601	3337	0.86	1.15	0.455	0.544	0.05	0.20	0.799	0.833
CHEMI	ALT (SGPT)	U/L	602	3294	-1.35	0.74	0.070	0.131	-0.13	0.17	0.460	0.593
CHEMI	AST (SGOT)	U/L	602	3285	-1.74	0.49	3.8E-04	0.004	-0.20	0.10	0.052	0.177
CHEMI	Urea Nitrogen	mmol/L	601	3326	0.15	0.12	0.206	0.297	0.03	0.02	0.218	0.411
CHEMI	Serum Uric Acid	umol/L	602	3342	-9.59	5.08	0.060	0.121	-2.43	0.92	0.009	0.054

N_{ppl}, Number of participants in the analysis; N_{obj}, Number of observations in the analysis; Beta, beta coefficient; SE, standard error of the beta coefficient; P_{FDR}, FDR adjusted P; HR, heart rate; SBP, systolic blood pressure; MBP, mean blood pressure; HEMAT, Hematology test; CHEMI, chemistry test.

Supplemental Table 2. Associations between the progression biomarkers and the MDS-UPDRS sub-scores of patients with PD at baseline

Test Group	Test Name	Unit	Outcome	Beta	SE	Praw
Vital Sign	Height	cm	UPDRS1	0.066	0.029	0.023
Vital Sign	Height	cm	UPDRS2	0.054	0.030	0.075
Vital Sign	Height	cm	UPDRS3	0.092	0.063	0.145
Hematology	Hemoglobin	g/L	UPDRS1	-0.064	0.019	0.001
Hematology	Hemoglobin	g/L	UPDRS3	-0.051	0.043	0.231
Hematology	Hemoglobin	g/L	UPDRS2	-0.005	0.020	0.805
Chemistry	Albumin-QT	g/L	UPDRS1	-0.183	0.076	0.016
Chemistry	Albumin-QT	g/L	UPDRS2	-0.078	0.079	0.327
Chemistry	Albumin-QT	g/L	UPDRS3	-0.011	0.166	0.946
Chemistry	Serum Sodium	mmol/L	UPDRS3	-0.266	0.195	0.173
Chemistry	Serum Sodium	mmol/L	UPDRS2	-0.099	0.093	0.288
Chemistry	Serum Sodium	mmol/L	UPDRS1	-0.091	0.090	0.311
Chemistry	Serum Potassium	mmol/L	UPDRS1	0.140	0.604	0.817
Chemistry	Serum Potassium	mmol/L	UPDRS2	0.055	0.627	0.930
Chemistry	Serum Potassium	mmol/L	UPDRS3	-0.007	1.316	0.996
Chemistry	Serum Bicarbonate	mmol/L	UPDRS3	-0.406	0.186	0.029
Chemistry	Serum Bicarbonate	mmol/L	UPDRS2	-0.100	0.089	0.261
Chemistry	Serum Bicarbonate	mmol/L	UPDRS1	-0.057	0.086	0.510
Chemistry	Serum Chloride	mmol/L	UPDRS1	0.030	0.087	0.726
Chemistry	Serum Chloride	mmol/L	UPDRS2	0.009	0.090	0.917
Chemistry	Serum Chloride	mmol/L	UPDRS3	0.015	0.189	0.935

Highlight, FDR adjusted $P < 0.05$. "

Supplemental Table 3. Genetic correlations between Parkinson's disease and the nominated biomarkers

Phenotype 1	Phenotype 2	rg	SE	P	h2_obs	h2_obs_SE	h2_int	h2_int_SE	gcov_int	gcov_int_SE
Parkinson	Hemoglobin concentration	0.036	0.032	0.265	0.158	0.015	1.098	0.023	-0.009	0.006
Parkinson	Lymphocyte counts	-0.027	0.030	0.365	0.211	0.017	1.060	0.017	0.007	0.006
Parkinson	Lymphocyte percentage	-0.016	0.033	0.616	0.161	0.013	1.048	0.014	0.002	0.006
Parkinson	Monocyte percentage	-0.040	0.032	0.215	0.185	0.023	1.102	0.030	0.002	0.007
Parkinson	Neutrophil count	0.002	0.032	0.951	0.177	0.021	1.048	0.018	0.003	0.006
Parkinson	Neutrophil percentage	0.032	0.034	0.338	0.155	0.013	1.038	0.015	-0.001	0.006

rg, genetic correlation; SE, standard error; h² obs, narrow-sense heritability observed; h² int, narrow-sense heritability intercept, gcov_int, cross-trait intercept.

Supplemental Table 4. Two-sample Mendelian randomization between Parkinson's disease and the nominated biomarkers

Exposure	Outcome	no. of SNPs	IVW			MR Egger		
			beta	se	P	beta	se	P
Hemoglobin concentration	Parkinson	110	-0.03	0.08	0.75	-0.02	0.16	0.91
Parkinson	Hemoglobin concentration	62	-0.01	0.01	0.14	-0.03	0.02	0.10
Lymphocyte counts	Parkinson	141	-0.11	0.06	0.06	0.25	0.15	0.11
Parkinson	Lymphocyte counts	62	-0.01	0.01	0.23	0.00	0.02	0.82
Lymphocyte percentage	Parkinson	116	-0.04	0.10	0.68	0.12	0.28	0.67
Parkinson	Lymphocyte percentage	62	0.00	0.01	0.82	0.06	0.02	0.02
Monocyte percentage	Parkinson	161	-0.01	0.05	0.76	-0.02	0.09	0.86
Parkinson	Monocyte percentage	62	-0.01	0.01	0.57	-0.01	0.02	0.51
Neutrophil count	Parkinson	120	-0.01	0.07	0.90	-0.19	0.15	0.21
Parkinson	Neutrophil count	62	-0.01	0.01	0.33	-0.07	0.03	0.02
Neutrophil percentage	Parkinson	116	0.06	0.08	0.49	0.14	0.20	0.49
Parkinson	Neutrophil percentage	62	0.00	0.01	0.82	-0.06	0.02	0.02

Model specifications

Linear mixed model

For height, weight, and BMI:

OUTCOME ~ PD*START + FEMALE + AGEatBL + AMTDN + LDOPA + MAOBI + PRMXL + RPNRL + (START|PATNO)

Outcome other than above:

OUTCOME ~ PD*START + FEMALE + AGEatBL + BMI + AMTDN + LDOPA + MAOBI + PRMXL + RPNRL + (START|PATNO)

Linear model for each visit

OUTCOME ~ PD + FEMALE + AGEatBL + BMI

* PD, indicator variable for PD; AGEatBL, age at baseline; AMTDN, amantadine dose; MAOBI, MAO-B inhibitor dose; LDOPA, Levodopa dose; PRMXL, pramipexole dose; RPNRL, ropinirol dose.

Prediction models and its selection

The following algorithms in python were tested with default hyper parameters.

Function Name	Package (python)
LogisticRegression	sklearn.linear_model
SGDClassifier	sklearn.linear_model
RandomForestClassifier	sklearn.ensemble
AdaBoostClassifier	sklearn.ensemble

GradientBoostingClassifier	sklearn.ensemble
BaggingClassifier	sklearn.ensemble
SVC	sklearn.svm
MLPClassifier	sklearn.neural_network
KNeighborsClassifier	sklearn.neighbors
LinearDiscriminantAnalysis	sklearn.discriminant_analysis
QuadraticDiscriminantAnalysis	sklearn.discriminant_analysis
XGBClassifier	xgboost

The prediction abilities of the differentiating biomarkers were evaluated using baseline data. All algorithms were tested with 5-fold cross validation and one with the largest mean area under the curve were selected for reporting.

Model 1 variables: AGEatBL, FEMALE, BMI, α -synuclein

Model 2 variables: AGEatBL, FEMALE, BMI, Neutrophil %, Monocyte %, Albumin, AST, Serum Sodium

Model 3 variables: AGEatBL, FEMALE, BMI, Neutrophil %, Monocyte %, Albumin, AST, Serum Sodium, systolic blood pressure at standing, heart rate at standing position, and heart rate at supine position

Model 4 variables: AGEatBL, FEMALE, BMI, Neutrophil %, Monocyte %, Albumin, AST, Serum Sodium, systolic blood pressure at standing, heart rate at standing position, and heart rate at supine position, aSYN. α -synuclein

* AGEatBL, age at baseline